Scarica l'app Stockscreener
1.01
3.81%
-0.04
Dopo l'orario di chiusura:
1.02
0.01
+0.99%
Precedente Chiudi:
$1.05
Aprire:
$1.02
Volume 24 ore:
1.34M
Relative Volume:
0.78
Capitalizzazione di mercato:
$128.46M
Reddito:
$79.18M
Utile/perdita netta:
$-136.99M
Rapporto P/E:
-0.9576
EPS:
-1.0547
Flusso di cassa netto:
$-120.11M
1 W Prestazione:
-10.62%
1M Prestazione:
-17.89%
6M Prestazione:
-74.69%
1 anno Prestazione:
-68.34%
Intervallo 1D:
$1.00
$1.04
Intervallo di 1 settimana:
$0.9393
$1.23
Portata 52W:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Nome
Adc Therapeutics Sa
Settore
Telefono
41 21 653 02 00
Indirizzo
BIOPOLE, EPALINGES
Compare ADCT vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.01 | 156.45M | 79.18M | -136.99M | -120.11M | -1.0547 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Iniziato | Guggenheim | Buy |
| 2023-08-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Iniziato | CapitalOne | Overweight |
| 2022-11-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-08-17 | Ripresa | Jefferies | Buy |
| 2021-08-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-09 | Iniziato | BofA/Merrill | Buy |
| 2020-06-09 | Iniziato | Cowen | Outperform |
Mostra tutto
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing - Stock Titan
ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says - marketscreener.com
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary - Yahoo Finance
ADCT|ADC Therapeutics SA|Price:1.050|Chg%:-0.180 - TradingKey
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo! Finance Canada
ADC Therapeutics SA (ADCT) Latest Stock News & Headlines - Yahoo Finance
ADC Therapeutics Q2 Earnings Call Highlights - MarketBeat
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS - marketbeat.com
ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968 - marketscreener.com
ADC Therapeutics Q2 Results: Net Loss Falls 71% to $16.6 Million - scanx.trade
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Nigeria
ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall - Investing.com
ADC Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings - quiverquant.com
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss - TradingKey
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - PR Newswire
Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside - GuruFocus
ADC Therapeutics SA expected to post a loss of 21 cents a shareEarnings Preview - TradingView
ADC Therapeutics SA (ADCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ADC Therapeutics SA (ADCT) Stock News Today - TradingKey
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - Morningstar
ADC Therapeutics (ADCT) to Post Quarterly Earnings on Tuesday - marketbeat.com
BlackRock (NYSE: BLK) discloses 5.4% ownership of ADC Therapeutics (ADCT) - Stock Titan
ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT - MarketBeat
ADC Therapeutics SA (ADCT) Income Statement - TradingKey
ADCT|ADC Therapeutics SA|Price:1.130|Chg%:+0.005 - TradingKey
ADC Therapeutics SA (ADCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ADCT|ADC Therapeutics SA|Price:1.139|Chg%:-0.000 - TradingKey
ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey
ADC Therapeutics SA (ADCT) Cash Flow - TradingKey
ADC Therapeutics SA (ADCT) Balance Sheet - TradingKey
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus
ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - Ad-hoc-news.de
ADC Therapeutics (NYSE:ADCT) Shares Down 6.3%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA - The National Law Review
ADC Therapeutics (ADCT) Holds Steady at $1.35 as Key Support and Resistance Levels NarrowPairs Trade - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeut - The National Law Review
ADC Therapeutics (ADCT) Holds Near Support Amid Slight Decline – Technical AnalysisVWAP Breakout - dars.gov.et
Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - Moomoo
Biocytogen and Whitehawk partner to develop ADCs - Pharmaceutical Technology
The ZYNLONTA therapy. ADCT targets US lymphoma patients with a focused antibody-drug treatment - ad-hoc-news.de
Adc Therapeutics Sa Azioni (ADCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
5.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):